Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for…
Biotechnology
US, Pasadena [HQ]
Ratios
15 Records · Starting from 2009Margins, Growth Rates In %
| Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 95.72 | 94.81 | |
| Profit Margin | -511.73 | -931.15 | -1,056.56 | -14,383.61 | -10,729.22 | -33,502.97 | -24,068.29 | -51,614.64 | -109.46 | -337.32 | 40.27 | -96.09 | -101.85 | -72.56 | -85.27 | |
| Operating Margin | -522.87 | -1,419.46 | -3,319.48 | -14,358.61 | -8,471.29 | -30,443.59 | -25,124.08 | -51,627.09 | -117.79 | -346.52 | 36.25 | -105.87 | -107.77 | -73.39 | -85.16 | |
|
EPS Growth
|
38.21 | 78.92 | 51.11 | -331.82 | 31.58 | 3.85 | -28.00 | 16.25 | 64.93 | -38.30 | 210.77 | -216.67 | -61.91 | -22.79 | -14.97 | |
| EPS USD | -427.00 | -90.00 | -44.00 | -190.00 | -130.00 | -125.00 | -160.00 | -134.00 | -47.00 | -65.00 | 72.00 | -84.00 | -136.00 | -167.00 | -192.00 | |
| Return on Assets (ROA) | -250.69 | -46.74 | -19.69 | -127.82 | -83.43 | -32.07 | -69.51 | -63.76 | -33.05 | -48.79 | 19.43 | -16.18 | -19.83 | -25.51 | -26.81 | |
| Return on Equity (ROE) | -397.46 | -63.83 | -24.46 | -210.99 | -113.25 | -35.20 | -83.45 | -85.50 | -42.22 | -56.84 | 27.79 | -18.31 | -34.45 | -166.57 | -75.65 | |
| Return on Invested Capital (ROIC) | -325.16 | -51.39 | -16.04 | -169.20 | -98.70 | -31.80 | -86.52 | -83.15 | -44.07 | -57.01 | 23.82 | -19.29 | -34.31 | -97.27 | -53.75 | |
| Solvency | ||||||||||||||||
| Equity Ratio | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 15.93 | 4.05 | 3.82 | 14.14 | 6.17 | 0.56 | 0.57 | 2.13 | 2.44 | 2.08 | 3.33 | 4.05 | 3.60 | 11.79 | 15.04 | |
| Debt/Equity | 25.25 | 5.53 | 4.74 | 23.34 | 8.38 | 0.61 | 0.69 | 2.85 | 3.11 | 2.43 | 4.76 | 4.58 | 6.25 | 76.99 | 42.45 | |
| Debt/EBITDA | 4.22 | 64.55 | 64.59 | 5.62 | 113.24 | 316.89 | 83.35 | 111.55 | 67.19 | 53.82 | -337.96 | 140.39 | 112.87 | 14.81 | -2.28 | |
|
Debt/Capitalization
|
20.16 | 5.24 | 4.53 | 18.92 | 7.73 | 0.61 | 0.68 | 2.77 | 3.02 | 2.37 | 4.54 | 4.38 | 5.88 | 43.50 | 29.80 | |
| Long-Term Debt/Capitalization | 9.33 | - - | 4.53 | 17.49 | 3.88 | 0.45 | 0.49 | 2.58 | 2.78 | 2.15 | - - | 4.16 | 5.39 | 42.65 | 27.82 | |
| Interest Debt per Share USD | 0.27 | 0.08 | 0.08 | 0.21 | 0.10 | 0.02 | 0.01 | 0.04 | 0.03 | 0.03 | 74.25 | 91.46 | 0.31 | 0.82 | 1.25 | |
| Debt Growth | -20.20 | -59.24 | 21.36 | 285.09 | -1.40 | -55.63 | -25.82 | 259.70 | -7.12 | -8.23 | -100.00 | - - | 20.85 | 219.34 | 41.18 | |
| Liquidity | ||||||||||||||||
| Current Ratio | 105.94 | 190.16 | 381.93 | 123.26 | 330.59 | 1,306.66 | 646.97 | 352.92 | 363.10 | 637.03 | 273.25 | 792.43 | 262.46 | 507.96 | 12,804.97 | |
| Quick Ratio | 92.46 | 181.88 | 377.64 | 111.66 | 323.53 | 1,301.29 | 621.07 | 333.19 | 351.19 | 621.60 | 267.19 | 777.60 | 257.99 | 509.87 | 46,608.08 | |
| Cash Ratio | 86.18 | 160.12 | 290.76 | 63.39 | 219.08 | 1,118.51 | 510.76 | 332.89 | 132.82 | 243.70 | 228.50 | 352.94 | 125.86 | 145.76 | 12,804.97 | |
| Operating Cash Flow Ratio | -600 | -100 | -200 | -200 | -200 | -200 | -400 | -200 | -100 | -300 | 100 | -200 | 100 | -100 | -17,700 | |
| Turnover | ||||||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -48.21 | - - | |
| Receivables Turnover | 2,562.29 | 66.63 | 18.41 | 5.96 | 346.95 | - - | - - | 211.11 | 46,326.10 | 4,930.84 | 25,522.46 | 10,404.98 | 1,348.48 | 17,250.43 | - - | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 363.35 | 34.83 | |
|
Asset Turnover
|
48.99 | 5.02 | 1.86 | 0.89 | 0.78 | 0.10 | 0.29 | 0.12 | 30.19 | 14.46 | 48.25 | 16.84 | 19.47 | 35.15 | 31.45 | |
| Fixed Turnover | 715.91 | 438.95 | 1,164.21 | 3.00 | 8.26 | 4.52 | 8.44 | 1.03 | 202.46 | 115.84 | 727.10 | 187.15 | 209.46 | 144.28 | 71.74 | |
| Coverage | ||||||||||||||||
| Interest Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 0.88 | -1.01 | -2,435.23 | -3,546.73 | -1,118.64 | |
| Asset Coverage | 300 | 1,300 | 1,900 | 200 | 1,100 | 16,600 | 12,100 | 2,900 | 2,500 | 3,400 | - - | 2,200 | 2,100 | 700 | 600 | |
| Cash Flow Coverage (CFGR) | -1,245.58 | -1,539.86 | -888.40 | -656.50 | -826.09 | -3,464.28 | -8,664.66 | -2,361.91 | -944.89 | -2,031.10 | 1,487.25 | -451.28 | 670.28 | -166.88 | -133.62 | |
| EBITDA Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -2,300 | -3,500 | -1,000 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | 100 | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -64.28 | -8.55 | -11.19 | -73.93 | -22.85 | -8.46 | -27.83 | -18.23 | -10.85 | -3.39 | 2.57 | -1.95 | -2.18 | -5.07 | -7.16 | |
|
Price/Earnings (P/E)
|
-1.5557 | -11.7006 | -8.9394 | -1.3526 | -4.3769 | -11.8160 | -3.5934 | -5.4851 | -9.2128 | -29.5075 | 38.9106 | -51.2943 | -45.9843 | -19.7419 | -13.9733 | |
| Price/Earnings Growth (PEG) | 4.07 | 14.83 | 17.49 | -0.41 | 13.86 | 307.22 | -12.83 | 33.75 | 14.19 | -77.05 | -18.46 | 23.67 | -74.28 | -86.61 | -93.34 | |
|
Price/Book (P/B)
|
618.32 | 746.87 | 218.67 | 285.39 | 495.70 | 415.98 | 299.87 | 468.99 | 389.01 | 1,677.20 | 1,081.37 | 939.22 | 1,584.26 | 3,288.34 | 1,057.10 | |
| Price/Tangible Book (P/TB) | 618.32 | 746.87 | 218.67 | 285.39 | 495.70 | 415.98 | 299.87 | 468.99 | 389.01 | 1,677.20 | 1,081.37 | 939.22 | 1,584.26 | 3,288.34 | 1,057.10 | |
| Price/Sales (P/S) | 796.08 | 10,895.00 | 9,445.05 | 19,455.66 | 46,960.49 | 395,871.04 | 86,488.12 | 283,110.34 | 1,008.47 | 9,953.31 | 1,566.95 | 4,928.97 | 4,683.59 | 1,432.52 | 1,191.51 | |
|
Price/Cash Flow (P/CF)
|
-196.61 | -877.48 | -518.86 | -186.28 | -716.17 | -1,956.08 | -502.81 | -695.75 | -1,323.11 | -3,402.33 | 1,528.56 | -4,546.63 | 3,782.65 | -2,559.54 | -1,863.91 | |
| Price/Free CF (P/FCF) | -196.10 | -876.86 | -517.93 | -180.63 | -705.17 | -1,865.62 | -488.17 | -656.42 | -994.24 | -3,302.92 | 1,642.48 | -4,040.40 | 4,386.38 | -1,844.46 | -867.56 | |
| Price/Operating CF (P/OCF) | -196.61 | -877.48 | -518.86 | -186.28 | -716.17 | -1,956.08 | -502.81 | -695.75 | -1,323.11 | -3,402.33 | 1,528.56 | -4,546.63 | 3,782.65 | -2,559.54 | -1,863.91 |